 PHILADELPHIA, April 06, 2022 GLOBE NEWSWIRE -- Cabaletta Bio, Inc. Nasdaq: CABA, a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Gwendolyn Binder, Ph.D., President of Science and Technology, will present a pre-recorded company presentation at the 21st Annual Needham Virtual Healthcare Conference, which will become available for on-demand viewing on Tuesday, April 12, 2022 at 3:45 p.m. ET. 